


## CLAIMS

1. A pharmaceutical composition containing a compound having general formula (I):

[Chemical Formula 1]



(wherein R<sup>1</sup> represents a methyl group or an ethyl group, R<sup>2</sup> represents a methyl group or an ethyl group, and R<sup>3</sup> represents a phenyl group substituted with 1 to 3 substituents selected from the group consisting of a halogen atom, a lower alkyl group, a cycloalkyl group, a lower alkoxy group, a halogeno lower alkyl group, a lower aliphatic acyl group and a cyano group), a pharmacologically acceptable salt thereof or a pharmacologically acceptable ester thereof.

2. A pharmaceutical composition according to claim 1, wherein R<sup>1</sup> is a methyl group.

3. A pharmaceutical composition according to claim 1 or 2, wherein R<sup>2</sup> is a methyl group.

4. A pharmaceutical composition according to any of claims 1 to 3, wherein R<sup>3</sup> is a phenyl group substituted with 1 to 3 substituents selected from the group consisting of a lower alkyl group, a cycloalkyl group and a lower alkoxy group.

5. A pharmaceutical composition according to any of claims 1 to 3, wherein R<sup>3</sup> is a phenyl group substituted with 1 to 3 substituents selected from the group consisting of a lower alkyl group and a lower alkoxy group.

6. A pharmaceutical composition according to any of claims 1 to 3 wherein R<sup>3</sup> is a phenyl group substituted with 1 to 3 substituents selected from the group consisting of a methyl group and a methoxy group.

7. A pharmaceutical composition containing any one of the compounds selected from the following or a pharmacologically acceptable salt thereof:

(2R)-2-amino-2-methyl-4-{1-methyl-5-[4-(3-methylphenyl)butanoyl]pyrrol-2-yl}butan-1-ol,

(2R)-2-amino-2-methyl-4-{1-methyl-5-[4-(4-methylphenyl)butanoyl]pyrrol-2-yl}butan-1-ol,  
(2R)-2-amino-2-methyl-4-{1-methyl-5-[4-(3,4-dimethylphenyl)butanoyl]pyrrol-2-yl}butan-1-ol,  
(2R)-2-amino-2-methyl-4-{1-methyl-5-[4-(4-methoxyphenyl)butanoyl]pyrrol-2-yl}butan-1-ol and  
(2R)-2-amino-2-methyl-4-{1-methyl-5-[4-(3-methyl-4-methoxyphenyl)butanoyl]pyrrol-2-yl}butan-1-ol.

8. A pharmaceutical composition according to any of claims 1 to 7 wherein the pharmacologically acceptable salt is a fumarate.

9. A pharmaceutical composition according to any of claims 1 to 8 having peripheral blood lymphocyte count lowering activity.

10. A pharmaceutical composition according to any of claims 1 to 8 that is a peripheral blood lymphocyte count lowering agent.

11. A pharmaceutical composition according to any of claims 1 to 8 that inhibits increases in peripheral blood lymphocyte count.

12. A pharmaceutical composition according to any of claims 1 to 8 for treatment or prophylaxis of diseases caused by abnormal peripheral blood lymphocyte count.

13. A pharmaceutical composition according to any of claims 1 to 8 for prophylaxis or treatment of diseases for which symptoms can be improved by lowering peripheral blood lymphocyte count.

14. A pharmaceutical composition according to any of claims 1 to 8 that exhibits immunosuppressive effects through peripheral blood lymphocyte count lowering activity.

15. A pharmaceutical composition according to any of claims 1 to 8 for suppressing rejection reactions during skin transplants or organ transplants.

16. A pharmaceutical composition according to any of claims 1 to 8 for prophylaxis or treatment of autoimmune diseases.

17. A pharmaceutical composition according to claim 16 wherein the autoimmune diseases are one or more types selected from the group consisting of rheumatoid arthritis, psoriasis, atopic dermatitis, multiple sclerosis, ulcerative colitis and Crohn's

disease.

18. A pharmaceutical composition according to any of claims 1 to 17 for administering orally to human adults at a dose of the active ingredient of 0.0001 mg/kg/day to 1 mg/kg/day.